![]() |
|
|
Vol. 289, Issue 2, 976-980, May 1999
Scios Incorporated, Mountain View, California
Although the synthetic version of the cardiac peptide human brain
natriuretic peptide (hBNP) has demonstrated beneficial cardiovascular effects in clinical studies, little is known about mechanisms governing
its elimination from the blood. This study measured the role of the
kidney, the natriuretic peptide clearance (NP-C) receptor, and
peptidase digestion on the elimination of synthetic hBNP from the
plasma compartment of rabbits. The estimated plasma steady state
resulting from a continuous i.v. infusion was achieved within 50 min
and was related in a linear manner with the infusion rate of the drug.
Complete restriction of kidney blood flow by bilateral suture-ligation
of the renal arteries compared with sham-treated animals reduced the
clearance of hBNP by approximately half (24 ± 9 ml/min versus
47 ± 14 ml/min, respectively, p < .007). Pharmacological blockade of the NP-C receptor with a clearance receptor-specific analog of atrial natriuretic peptide increased in a
statistically significant and dose-related manner the plasma steady-state level of hBNP during continuous i.v. infusion of hBNP
(maximum effect of 1.9 ± 0.3-fold, p < .01).
The peptidase inhibitor phosphoramidon increased in a dose-related
manner the plasma steady-state level of hBNP 1.7 ± 0.4-fold
during continuous i.v. infusion of hBNP in rabbits. These data suggest
that the kidney, the NP-C receptor, and peptidases are all important in the elimination of hBNP from the plasma compartment.
This article has been cited by other articles:
![]() |
S. Vickery, M. C. Webb, C. P. Price, R. I. John, N. A. Abbas, and E. J. Lamb Prognostic value of cardiac biomarkers for death in a non-dialysis chronic kidney disease population Nephrol. Dial. Transplant., November 1, 2008; 23(11): 3546 - 3553. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. Liang, J. O'Rear, U. Schellenberger, L. Tai, M. Lasecki, G. F. Schreiner, F. S. Apple, A. S. Maisel, N. S. Pollitt, and A. A. Protter Evidence for Functional Heterogeneity of Circulating B-Type Natriuretic Peptide J. Am. Coll. Cardiol., March 13, 2007; 49(10): 1071 - 1078. [Abstract] [Full Text] [PDF] |
||||
![]() |
I Raymond, B A Groenning, P R Hildebrandt, J C Nilsson, M Baumann, J Trawinski, and F Pedersen The influence of age, sex and other variables on the plasma level of N-terminal pro brain natriuretic peptide in a large sample of the general population Heart, July 1, 2003; 89(7): 745 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
J.-Z. Sun, S.-J. Chen, G. Li, and Y.-F. Chen Hypoxia reduces atrial natriuretic peptide clearance receptor gene expression in ANP knockout mice Am J Physiol Lung Cell Mol Physiol, September 1, 2000; 279(3): L511 - L519. [Abstract] [Full Text] [PDF] |
||||